ArticleACS omega2025
SNaP-C: Development of a Silver Nanoparticle Antioxidant Assay for the Selective Quantitative Analysis of Vitamin C in Beverages.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quantifying the Antioxidant Capacity of Inorganic Nanoparticles: Challenges and Analytical Solutions.Antioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of a sensitive and selective silver nanoparticle assay for the quantitation of vitamin C (SNaP-C), as ascorbic acid (AA) and total ascorbic acid (TAA = AA + dehydroascorbic acid, DHAA), is described. Three assay parameters were investigated and optimized: (1) synthesis of silver nanoparticles (AgNPs) to produce a reliable enhanced localized surface plasmon resonance (LSPR) in the presence of specific added antioxidants; (2) ensuring long-term stability of AA and DHAA in aqueous solutions; and (3) SNaP-C assay conditions to allow for rapid analysis of samples (beverages) by monitoring the enhanced LSPR. The synthesis of AgNPs using soluble starch as a capping agent and d-arabinose as a reducing agent was optimized in a CEM Discover SP laboratory microwave. Given that AA and DHAA lack aqueous stability, these forms were stabilized via the addition of 1% (w/v) meta-phosphoric acid. To convert DHAA to AA, the reducing agent tris(2-carboxyethyl) phosphine hydrochloride (TCEP) was added with its concentration (2.5 mM) and reaction time (24 h) optimized. Using a Box-Behnken design for three factors, the SNaP-C assay reaction conditions of 1000 μL of AgNPs (in suspension) with 100 μL of beverage (or analytical standard) and 4.9 mL of water using the CEM Discover SP microwave were optimized, resulting in an incubation time of 90 °C for 6 min. Finally, a list of potential interferents that commonly respond to other antioxidant capacity assays, like the Folin-Ciocalteu, were investigated to demonstrate that the SNaP-C assay is selective and sensitive for ascorbic acid and gallic acid.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.